Results 1 to 10 of about 136,040,587 (306)

A Serpin With a Finger in Many PAIs: PAI-1's Central Function in Thromboinflammation and Cardiovascular Disease

open access: yesFrontiers in Cardiovascular Medicine, 2021
Plasminogen activator inhibitor 1 (PAI-1) is a member of the serine protease inhibitor (serpin) superfamily. PAI-1 is the principal inhibitor of the plasminogen activators, tissue plasminogen activator (tPA), and urokinase-type plasminogen activator (uPA)
Claire Whyte   +2 more
exaly   +2 more sources

Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition

open access: yesFrontiers in Cardiovascular Medicine, 2020
Plasminogen activator inhibitor-1 (PAI-1), a member of the serine protease inhibitor (serpin) superfamily with antiprotease activity, is the main physiological inhibitor of tissue-type (tPA) and urokinase-type (uPA) plasminogen activators (PAs).
Machteld Sillen, Paul J. Declerck
doaj   +2 more sources

Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphisms and risk of venous thromboembolism – a meta-analysis and systematic review

open access: yesVasa - European Journal of Vascular Medicine, 2020
Background: A 4G/5G polymorphism in the promoter region of the plasminogen activator inhibitor type 1 (PAI-1) gene has been reported to enhance the plasma levels of PAI-1, which plays an important role in fibrinolysis disorders and venous thromboembolism,
Mingfang Xu, Qiang Zhang
exaly   +2 more sources

PAI-1 Exacerbates White Adipose Tissue Dysfunction and Metabolic Dysregulation in High Fat Diet-Induced Obesity

open access: yesFrontiers in Pharmacology, 2018
Background: Plasminogen activator inhibitor (PAI)-1 levels and activity are known to increase during metabolic syndrome and obesity. In addition, previous studies have implicated PAI-1 in adipose tissue (AT) expansion while also contributing to insulin ...
Lin Wang   +26 more
doaj   +2 more sources

Reversing PAI-1 deficiency in blood using mRNA lipid nanoparticles [PDF]

open access: yesMolecular Therapy: Methods & Clinical Development
Plasminogen activator inhibitor-1 (PAI-1) deficiency is a rare disorder that causes moderate to severe bleeding and cardiac fibrosis, caused by mutation in the SERPINE-1 gene and no detectable circulating PAI-1 protein.
Francesca Ferraresso   +11 more
doaj   +2 more sources

Influence of high intensity interval training on adipose tissue PAI-2 and MMP-2 mRNAs expression in rat with high-fat diet-induced metabolic syndrome [PDF]

open access: yesJournal of Exercise & Organ Cross Talk, 2022
The aim of this study was to investigate the influence of high intensity interval training on adipose tissue PAI-2 and MMP-2 mRNAs expression in rat with high-fat diet-induced metabolic syndrome.
Mojgan Banihashemi   +3 more
doaj   +1 more source

Past, Present, and Future Perspectives of Plasminogen Activator Inhibitor 1 (PAI-1)

open access: yesSeminars in Thrombosis and Hemostasis, 2022
Plasminogen activator inhibitor 1 (PAI-1), a SERPIN inhibitor, is primarily known for its regulation of fibrinolysis. However, it is now known that this inhibitor functions and contributes to many (patho)physiological processes including inflammation ...
G. Morrow, N. Mutch
semanticscholar   +1 more source

Upaya Meningkatkan Hasil Belajar Siswa Kelas VIII A SMP Negeri 1 Buntulia Pada Mata Pelajaran Pendidikan Agama Islam Melalui Penerapan Model Pembelajaran Kooperatif tipe Think Talk Write

open access: yesAksara, 2021
Penelitian ini merupakan Penelitian Tindakan Kelas (PTK) dengan mencoba menerapan salah satu model pembelajaran untuk mengaktifkansiswa dan mengefektifkan proses pembelajaran yaitu pembelajaran kooperatif tipe Think Talk Write.
Warni Diange
doaj   +1 more source

PAI-1 in Diabetes: Pathophysiology and Role as a Therapeutic Target

open access: yesInternational Journal of Molecular Sciences, 2021
Hypofibrinolysis is a key abnormality in diabetes and contributes to the adverse vascular outcome in this population. Plasminogen activator inhibitor (PAI)-1 is an important regulator of the fibrinolytic process and levels of this antifibrinolytic ...
Rawan Altalhi, N. Pechlivani, R. Ajjan
semanticscholar   +1 more source

Role of PAI-1 in hepatic steatosis and dyslipidemia

open access: yesScientific Reports, 2021
Plasminogen activator inhibitor 1 (PAI-1) is a functional biomarker of the metabolic syndrome. Previous studies have demonstrated that PAI-1 is a mechanistic contributor to several elements of the syndrome, including obesity, hypertension and insulin ...
J. A. Levine   +15 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy